(Q36961866)

17 August 2017

1 reference

title

Advances in the diagnosis and treatment of osteoporosis (English)

1 reference

17 August 2017

Jill Simmons

1

1 reference

17 August 2017

Phil Zeitler

series ordinal

2

1 reference

17 August 2017

Joel Steelman

series ordinal

3

1 reference

17 August 2017

publication date

1 January 2007

1 reference

17 August 2017

published in

Advances in pediatrics

1 reference

17 August 2017

volume

54

1 reference

17 August 2017

page(s)

85-114

1 reference

Normal acquisition and loss of bone mass.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Quantitative bone analysis in children: current methods and recommendations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Males have larger skeletal size and bone mass than females, despite comparable body size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Bone mineral acquisition in healthy Asian, Hispanic, black, and Caucasian youth: a longitudinal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Reduced bone mass in daughters of women with osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

7 January 2021

Genetics of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Regional Specificity of Exercise and Calcium During Skeletal Growth in Girls: A Randomized Controlled Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

A positive dose-response effect of vitamin D supplementation on site-specific bone mineral augmentation in adolescent girls: a double-blinded randomized placebo-controlled 1-year intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Effects of calcium supplementation on bone density in healthy children: meta-analysis of randomised controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Teenaged girls, carbonated beverage consumption, and bone fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Nutritional rickets with normal circulating 25-hydroxyvitamin D: a call for reexamining the role of dietary calcium intake in North American infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Nutritional rickets in suburbia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Hypovitaminosis D in healthy schoolchildren

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Vitamin D: a necessity for children and adolescents in Greece

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

The relation of dietary vitamin C intake to bone mineral density: results from the PEPI study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Jumping improves hip and lumbar spine bone mass in prepubescent children: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

A school-based exercise intervention elicits substantial bone health benefits: a 2-year randomized controlled trial in girls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Effect of a calcium and exercise intervention on the bone mineral status of 16-18-y-old adolescent girls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Self-reported lifetime physical activity and areal bone mineral density in healthy postmenopausal women: the importance of teenage activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Alcohol intake as a risk factor for fracture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Smoking and fracture risk: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

A meta-analysis of the effects of cigarette smoking on bone mineral density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Smoking Is Associated with Lower Bone Mineral Density and Reduced Cortical Thickness in Young Men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Osteogenesis imperfecta, current and future medical treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Testing for osteogenesis imperfecta in cases of suspected non-accidental injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Type V osteogenesis imperfecta: a new form of brittle bone disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Genetic heterogeneity in osteogenesis imperfecta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Osteoporosis in adult patients with celiac disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Local and systemic factors in the pathogenesis of osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Reduced bone mineral content in adult patients with growth hormone deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Reduced bone mineral density in patients with adult onset growth hormone deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Low vertebral cancellous bone density in peripubertal girls with Turner's syndrome and boys with hypogonadism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

The skeletal phenotype of men with previous constitutional delay of puberty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Thyroid hormones increase insulin-like growth factor I content in the medium of rat bone tissue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-I) and IGF-II from neonatal mouse calvaria in organ culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Primary hyperparathyroidism in a paediatric hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Primary hyperparathyroidism in pediatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Osteopenia in children who have undergone posterior fossa or craniospinal irradiation for brain tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Cross-sectional study of bone mineral density in adult survivors of solid pediatric cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Bone mineral assessment with tibial ultrasonometry and dual-energy X-ray absorptiometry in long-term survivors of acute lymphoblastic leukemia in childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Normal bone mineral density after treatment for childhood acute lymphoblastic leukemia diagnosed between 1991 and 1998

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Bone mineral density and bone metabolism in children treated for bone sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Osteoporosis in women with anorexia nervosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Outcome of bone mineral density in anorexia nervosa patients 11.7 years after first admission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Diagnosis of osteoporosis in men, premenopausal women, and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Measuring bone mass in children: can we really do it?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Interpretation of whole body dual energy X-ray absorptiometry measures in children: comparison with peripheral quantitative computed tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Can geometry-based parameters from pQCT and material parameters from quantitative ultrasound (QUS) improve the prediction of radial bone strength over that by bone mass (DXA)?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

The role of ultrasound in the assessment of osteoporosis: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Bone mineral density in girls with forearm fractures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

More broken bones: a 4-year double cohort study of young girls with and without distal forearm fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Increased body weight and decreased radial cross-sectional dimensions in girls with forearm fractures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Bone-mineral density in children and adolescents who have spastic cerebral palsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Bone mineral density and bone metabolism in Duchenne muscular dystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Guide to bone health and disease in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Guidelines on the use of biochemical markers of bone turnover in osteoporosis (2001).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Relationship of bone turnover to bone density and fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Biochemical markers of bone turnover. Applications for osteoporosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

The predictive role of bone turnover markers for BMD in middle-aged men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Bone health in children and adolescents: a symposium at the annual meeting of the Pediatric Academic Societies/Lawson Wilkins Pediatric Endocrine Society, May 2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Rapid Increase in Grip Force After Start of Pamidronate Therapy in Children and Adolescents With Severe Osteogenesis Imperfecta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Short-term safety assessment in the use of intravenous zoledronic acid in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Biphosphonate-induced radiographic changes in two pediatric patients with rheumatic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Modern approach to children with osteogenesis imperfecta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Osteogenesis imperfecta in childhood: treatment strategies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Use of bisphosphonate therapy for osteoporosis in childhood and adolescence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Oral bisphosphonates to treat disuse osteopenia in children with disabilities: a case series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Adverse effects of bisphosphonates. A comparative review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Bisphosphonate-induced osteopetrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Insulin-like growth factors and bone: the osteoporosis connection revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Growth hormone improves bone mineral content in children with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

A retrospective study of growth hormone use in adolescents with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

New anabolic therapies in osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

The incorporation and removal of large amounts of strontium by physiologic mechanisms in mineralized tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Strontium induces murine keratinocyte differentiation in vitro in the presence of serum and calcium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Oral statins and increased bone-mineral density in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Slow-release sodium fluoride in osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

Age-specific fluoride exposure in drinking water and osteosarcoma (United States).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2007.03.007

10.1016/J.YAPD.2007.03.007

7 January 2021

Identifiers

DOI

1 reference

17 August 2017

1 reference